TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Sponsor: Karyopharm Therapeutics Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,374,450

Rescue Site Savings

+$903,210

Unlock Full NCT02343042 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02343042 Rescue Dossier →